The JCA Is Coming: Will the EU Band Together?

Author(s)

Bryan A1, Wu K1, Counihan J2, Hunt M1
1Trinity Life Sciences, New York, NY, USA, 2Trinity Life Sciences, Colorado Springs, CO, USA

OBJECTIVES: Health technology assessments (HTAs) act as the authorities to socialized funding of medicine in Europe. A positive HTA evaluation is essential for successful access and reimbursement. HTAs are becoming increasingly collaborative to promote transparency/objectivity and streamline drug review.

A new pan-European HTA regulation established January 2022 will require member states to give “due consideration” to joint clinical assessment (JCA) reports in their national HTA assessments starting in 2025. The JCA will focus on the clinical domain of HTAs but will not focus on economic assessments. Additionally, member states will remain free to conduct complementary clinical and non-clinical analyses.

METHODS: This regulation review considers the potential impact of widespread European adoption of the JCA as a new requirement for HTAs. N=8 ex-payer stakeholder interviews across Germany, France, Italy, and Spain add a primary research perspective on the impact of JCA.

RESULTS: As the EMA previously streamlined the European regulatory process, the JCA could do the same for clinical HTA assessments. These efficiencies may be attractive for manufacturers since only one clinical submission plus local economic assessment across Europe could be necessary. Conversely, the JCA may introduce redundancy if countries maintain their national approach in addition to the JCA process.

A major driver for JCA adoption will be the extent to which local clinical value priorities are reflected in the cross-board assessment and if, and how, environment differences (e.g., variation in local historic standard of care) can be accommodated.

CONCLUSIONS: The degree to which the JCA drives efficiency and lowers barriers to broad and speedy access remains unclear. Member states may forego their national clinical assessment processes completely, and use the JCA in its place, or conduct their own supplemental clinical assessment resulting in redundancy. For full integration, and thus substitution, states will need to have confidence in JCA’s parameters and evaluation criteria.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

HTA190

Topic

Health Policy & Regulatory, Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes, Reimbursement & Access Policy, Systems & Structure, Value Frameworks & Dossier Format

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×